Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability